Chien, Y. Novel Drug Delivery Systems (CRC Press, 1991). Show
Langer, R. Drug delivery and targeting. Nature 392, 5–10 (1998). CAS PubMed Google Scholar Langer, R. New methods of drug delivery. Science 249, 1527–1533 (1990). Article CAS PubMed Google Scholar Allen, T. M. & Cullis, P. R. Drug delivery systems: entering the mainstream. Science 303, 1818–1822 (2004). Article CAS PubMed Google Scholar Gidal, B. E. et al. Gabapentin bioavailability: effect of dose and frequency of administration in adult patients with epilepsy. Epilepsy Res. 31, 91–99 (1998). Article CAS PubMed Google Scholar Serajuddin, A. T. Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. J. Pharm. Sci. 88, 1058–1066 (1999). Article CAS PubMed Google Scholar Schmidt, B. et al. A natural history of botanical therapeutics. Metabolism 57, S3–S9 (2008). Article CAS PubMed PubMed Central Google Scholar Washington, N., Washington, C. & Wilson, C. Physiological Pharmaceutics: Barriers to Drug Absorption (CRC Press, 2000). Savjani, K. T., Gajjar, A. K. & Savjani, J. K. Drug solubility: importance and enhancement techniques. ISRN Pharm. 2012, 195727 (2012). PubMed PubMed Central Google Scholar Kalepu, S. & Nekkanti, V. Insoluble drug delivery strategies: review of recent advances and business prospects. Acta Pharm. Sinica B 5, 442–453 (2015). Article Google Scholar Sharma, P. C., Jain, A., Jain, S., Pahwa, R. & Yar, M. S. Ciprofloxacin: review on developments in synthetic, analytical, and medicinal aspects. J. Enzym. Inhib. Med. Chem. 25, 577–589 (2010). Article CAS Google Scholar Beaumont, K., Webster, R., Gardner, I. & Dack, K. Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: challenges to the discovery scientist. Curr. Drug Metab. 4, 461–485 (2003). Article CAS PubMed Google Scholar Kempf, D. J. et al. Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacy. J. Med. Chem. 41, 602–617 (1998). Article CAS PubMed Google Scholar Nelson, E. Kinetics of drug absorption, distribution, metabolism, and excretion. J. Pharm. Sci. 50, 181–192 (1961). Article CAS PubMed Google Scholar Teorell, T. Kinetics of distribution of substances administered to the body, I: the extravascular modes of administration. Arch. Int. Pharmacodyn. Ther. 57, 205–225 (1937). CAS Google Scholar Dost, F. H. Der Blutspiegel: Kinetik der Konzentrationsabläufe in der Kreislaufflüssigkeit (Georg Thieme, 1953). Kubitza, D., Becka, M., Wensing, G., Voith, B. & Zuehlsdorf, M. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct factor Xa inhibitor—after multiple dosing in healthy male subjects. Eur. J. Clin. Pharmacol. 61, 873–880 (2005). Article CAS PubMed Google Scholar Chien, S. C. et al. Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses. Antimicrob. Agents Chemother. 41, 2256–2260 (1997). Article CAS PubMed PubMed Central Google Scholar Park, K. Controlled drug delivery systems: past forward and future back. J. Control. Release 190, 3–8 (2014). Article CAS PubMed PubMed Central Google Scholar Keraliya, R. A. et al. Osmotic drug delivery system as a part of modified release dosage form. ISRN Pharm. 2012, 528079 (2012). PubMed PubMed Central Google Scholar Prausnitz, M. R. & Langer, R. Transdermal drug delivery. Nat. Biotechnol. 26, 1261–1268 (2008). Article CAS PubMed PubMed Central Google Scholar Anselmo, A. C. & Mitragotri, S. Nanoparticles in the clinic. Bioeng. Transl. Med. 1, 10–29 (2016). Article PubMed PubMed Central Google Scholar Anselmo, A. C. & Mitragotri, S. Nanoparticles in the clinic: an update. Bioeng. Transl. Med. 4, e10143 (2019). PubMed PubMed Central Google Scholar Albanese, A., Tang, P. S. & Chan, W. C. W. The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu. Rev. Biomed. Eng. 14, 1–16 (2012). Article CAS PubMed Google Scholar Champion, J. A., Katare, Y. K. & Mitragotri, S. Particle shape: a new design parameter for micro- and nanoscale drug delivery carriers. J. Control. Release 121, 3–9 (2007). Article CAS PubMed PubMed Central Google Scholar Champion, J. A., Walker, A. & Mitragotri, S. Role of particle size in phagocytosis of polymeric microspheres. Pharm. Res. 25, 1815–1821 (2008). Article CAS PubMed PubMed Central Google Scholar Win, K. Y. & Feng, S.-S. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials 26, 2713–2722 (2005). Article CAS PubMed Google Scholar Papahadjopoulos, D. et al. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc. Natl Acad. Sci. USA 88, 11460–11464 (1991). Article CAS PubMed PubMed Central Google Scholar Barenholz, Y. Doxil—the first FDA-approved nano-drug: lessons learned. J. Control. Release 160, 117–134 (2012). Article CAS PubMed Google Scholar Hopkins, A. L. & Groom, C. R. The druggable genome. Nat. Rev. Drug Discov. 1, 727–730 (2002). Article CAS PubMed Google Scholar Rask-Andersen, M., Masuram, S. & Schioth, H. B. The druggable genome: evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication. Annu. Rev. Pharmacol. Toxicol. 54, 9–26 (2014). Article CAS PubMed Google Scholar Lau, J. L. & Dunn, M. K. Therapeutic peptides: historical perspectives, current development trends, and future directions. Bioorg. Med. Chem. 26, 2700–2707 (2018). Article CAS PubMed Google Scholar Bruno, B. J., Miller, G. D. & Lim, C. S. Basics and recent advances in peptide and protein drug delivery. Ther. Deliv. 4, 1443–1467 (2013). Article CAS PubMed Google Scholar Craik, D. J., Fairlie, D. P., Liras, S. & Price, D. The future of peptide-based. Drugs Chem. Biol. Drug Des. 81, 136–147 (2013). Article CAS PubMed Google Scholar Putney, S. D. & Burke, P. A. Improving protein therapeutics with sustained-release formulations. Nat. Biotechnol. 16, 153–157 (1998). Article CAS PubMed Google Scholar Pisal, D. S., Kosloski, M. P. & Balu-Iyer, S. V. Delivery of therapeutic proteins. J. Pharm. Sci. 99, 2557–2575 (2010). Article CAS PubMed PubMed Central Google Scholar Schuster, J. et al. In vivo stability of therapeutic proteins. Pharm. Res. 37, 23 (2020). Article CAS PubMed Google Scholar Baker, M. P., Reynolds, H. M., Lumicisi, B. & Bryson, C. J. Immunogenicity of protein therapeutics: the key causes, consequences and challenges. Self Nonself 1, 314–322 (2010). Article PubMed PubMed Central Google Scholar Jawa, V. et al. T-cell dependent immunogenicity of protein therapeutics: preclinical assessment and mitigation. Clin. Immunol. 149, 534–555 (2013). Article CAS PubMed Google Scholar Rosenberg, A. S. & Sauna, Z. E. Immunogenicity assessment during the development of protein therapeutics. J. Pharm. Pharmacol. 70, 584–594 (2018). Article CAS PubMed Google Scholar Di, L. Strategic approaches to optimizing peptide ADME properties. AAPS J. 17, 134–143 (2015). Article CAS PubMed Google Scholar Ovadia, O. et al. Improvement of drug-like properties of peptides: the somatostatin paradigm. Expert Opin. Drug Discov. 5, 655–671 (2010). Article CAS PubMed Google Scholar Jevsevar, S., Kunstelj, M. & Porekar, V. G. PEGylation of therapeutic proteins. Biotechnol. J. 5, 113–128 (2010). Article CAS PubMed Google Scholar Brown, T. D., Whitehead, K. A. & Mitragotri, S. Materials for oral delivery of proteins and peptides. Nat. Rev. Mater. 5, 127–148 (2019). Article Google Scholar Drucker, D. J. Advances in oral peptide therapeutics. Nat. Rev. Drug Discov. 19, 277–289 (2020). Article CAS PubMed Google Scholar Suzuki, R., Brown, G. A., Christopher, J. A., Scully, C. C. G. & Congreve, M. Recent developments in therapeutic peptides for the glucagon-like peptide 1 and 2 receptors. J. Med. Chem. 63, 905–927 (2020). Article CAS PubMed Google Scholar Anselmo, A. C., Gokarn, Y. & Mitragotri, S. Non-invasive delivery strategies for biologics. Nat. Rev. Drug Discov. 18, 19–40 (2019). Article CAS PubMed Google Scholar Morales, J. O. et al. Challenges and future prospects for the delivery of biologics: oral mucosal, pulmonary, and transdermal routes. AAPS J. 19, 652–668 (2017). Article CAS PubMed Google Scholar Ritschel, W. Microemulsion technology in the reformulation of cyclosporine: the reason behind the pharmacokinetic properties of Neoral. Clin. Transplant. 10, 364–373 (1996). CAS PubMed Google Scholar Pfutzner, A., Mann, A. E. & Steiner, S. S. Technosphere/insulin—a new approach for effective delivery of human insulin via the pulmonary route. Diabetes Technol. Ther. 4, 589–594 (2002). Article PubMed Google Scholar Dlugi, A. M., Miller, J. D., Knittle, J. & Group, L. S. Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: a randomized, placebo-controlled, double-blind study. Fertil. Steril. 54, 419–427 (1990). Article CAS PubMed Google Scholar Mura, S., Nicolas, J. & Couvreur, P. Stimuli-responsive nanocarriers for drug delivery. Nat. Mater. 12, 991–1003 (2013). Article CAS PubMed Google Scholar Jain, D., Raturi, R., Jain, V., Bansal, P. & Singh, R. Recent technologies in pulsatile drug delivery systems. Biomatter 1, 57–65 (2011). Article PubMed PubMed Central Google Scholar Yu, J. et al. Microneedle-array patches loaded with hypoxia-sensitive vesicles provide fast glucose-responsive insulin delivery. Proc. Natl Acad. Sci. USA 112, 8260–8265 (2015). Article CAS PubMed PubMed Central Google Scholar Lu, R.-M. et al. Development of therapeutic antibodies for the treatment of diseases. J. Biomed. Sci. 27, 1 (2020). Article CAS PubMed PubMed Central Google Scholar Chames, P., Van Regenmortel, M., Weiss, E. & Baty, D. Therapeutic antibodies: successes, limitations and hopes for the future. Br. J. Pharmacol. 157, 220–233 (2009). Article CAS PubMed PubMed Central Google Scholar Shih, T. & Lindley, C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin. Ther. 28, 1779–1802 (2006). Article CAS PubMed Google Scholar Smith, M. R. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 22, 7359–7368 (2003). Article CAS PubMed Google Scholar Aarden, L., Ruuls, S. R. & Wolbink, G. Immunogenicity of anti-tumor necrosis factor antibodies—toward improved methods of anti-antibody measurement. Curr. Opin. Immunol. 20, 431–435 (2008). Article CAS PubMed Google Scholar Baert, F. et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N. Engl. J. Med. 348, 601–608 (2003). Article CAS PubMed Google Scholar Atzeni, F. et al. Immunogenicity and autoimmunity during anti-TNF therapy. Autoimmun. Rev. 12, 703–708 (2013). Article CAS PubMed Google Scholar Sgro, C. Side-effects of a monoclonal antibody, muromonab CD3/orthoclone OKT3: bibliographic review. Toxicology 105, 23–29 (1995). Article CAS PubMed Google Scholar Reichert, J. M. Marketed therapeutic antibodies compendium. mAbs 4, 413–415 (2012). Article PubMed PubMed Central Google Scholar Suzuki, M., Kato, C. & Kato, A. Therapeutic antibodies: their mechanisms of action and the pathological findings they induce in toxicity studies. J. Toxicol. Pathol. 28, 133–139 (2015). Article CAS PubMed PubMed Central Google Scholar Jones, P. T., Dear, P. H., Foote, J., Neuberger, M. S. & Winter, G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321, 522–525 (1986). Article CAS PubMed Google Scholar McCafferty, J., Griffiths, A. D., Winter, G. & Chiswell, D. J. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 348, 552–554 (1990). Article CAS PubMed Google Scholar Bradbury, A. R., Sidhu, S., Dubel, S. & McCafferty, J. Beyond natural antibodies: the power of in vitro display technologies. Nat. Biotechnol. 29, 245–254 (2011). Article CAS PubMed PubMed Central Google Scholar Chapman, A. P. PEGylated antibodies and antibody fragments for improved therapy: a review. Adv. Drug Deliv. Rev. 54, 531–545 (2002). Article CAS PubMed Google Scholar Ryman, J. T. & Meibohm, B. Pharmacokinetics of monoclonal antibodies. CPT Pharmacometrics Syst. Pharm. 6, 576–588 (2017). Article CAS Google Scholar Frost, G. I. Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration. Expert Opin. Drug Deliv. 4, 427–440 (2007). Article CAS PubMed Google Scholar Sugahara, K. N. et al. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science 328, 1031–1035 (2010). Article CAS PubMed PubMed Central Google Scholar Gabrilovich, D. I., Ishida, T., Nadaf, S., Ohm, J. E. & Carbone, D. P. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin. Cancer Res. 5, 2963–2970 (1999). CAS PubMed Google Scholar Wei, S. C. et al. Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade. Cell 170, 1120–1133.e17 (2017). Article CAS PubMed PubMed Central Google Scholar Meadows, K. L. & Hurwitz, H. I. Anti-VEGF therapies in the clinic. Cold Spring Harb. Perspect. Med. 2, a006577 (2012). Article PubMed PubMed Central CAS Google Scholar Alley, S. C., Okeley, N. M. & Senter, P. D. Antibody–drug conjugates: targeted drug delivery for cancer. Curr. Opin. Chem. Biol. 14, 529–537 (2010). Article CAS PubMed Google Scholar Beck, A., Goetsch, L., Dumontet, C. & Corvaïa, N. Strategies and challenges for the next generation of antibody–drug conjugates. Nat. Rev. Drug Discov. 16, 315–337 (2017). Article CAS PubMed Google Scholar Opalinska, J. B. & Gewirtz, A. M. Nucleic-acid therapeutics: basic principles and recent applications. Nat. Rev. Drug Discov. 1, 503–514 (2002). Article CAS PubMed Google Scholar Mali, P. et al. RNA-guided human genome engineering via Cas9. Science 339, 823–826 (2013). Article CAS PubMed PubMed Central Google Scholar de Smet, M. D., Meenken, C. & van den Horn, G. J. Fomivirsen—a phosphorothioate oligonucleotide for the treatment of CMV retinitis. Ocul. Immunol. Inflamm. 7, 189–198 (1999). Article PubMed Google Scholar Rinaldi, C. & Wood, M. J. A. Antisense oligonucleotides: the next frontier for treatment of neurological disorders. Nat. Rev. Neurol. 14, 9–21 (2018). Article CAS PubMed Google Scholar Kaczmarek, J. C., Kowalski, P. S. & Anderson, D. G. Advances in the delivery of RNA therapeutics: from concept to clinical reality. Genome Med. 9, 60 (2017). Article PubMed PubMed Central CAS Google Scholar Van Hoecke, L. & Roose, K. How mRNA therapeutics are entering the monoclonal antibody field. J. Transl. Med. 17, 54 (2019). Article PubMed PubMed Central Google Scholar Behlke, M. A. Chemical modification of siRNAs for in vivo use. Oligonucleotides 18, 305–320 (2008). Article CAS PubMed Google Scholar Kormann, M. S. et al. Expression of therapeutic proteins after delivery of chemically modified mRNA in mice. Nat. Biotechnol. 29, 154–157 (2011). Article CAS PubMed Google Scholar Khvorova, A. & Watts, J. K. The chemical evolution of oligonucleotide therapies of clinical utility. Nat. Biotechnol. 35, 238–248 (2017). Article CAS PubMed PubMed Central Google Scholar Endoh, T. & Ohtsuki, T. Cellular siRNA delivery using cell-penetrating peptides modified for endosomal escape. Adv. Drug Deliv. Rev. 61, 704–709 (2009). Article CAS PubMed Google Scholar Liang, W. & Lam, J. K. W. in Molecular Regulation of Endocytosis (ed. Ceresa, B) 429–456 (IntechOpen, 2012). Whitehead, K. A., Langer, R. & Anderson, D. G. Knocking down barriers: advances in siRNA delivery. Nat. Rev. Drug Discov. 8, 129–138 (2009). Article CAS PubMed PubMed Central Google Scholar Garber, K. Alnylam launches era of RNAi drugs. Nat. Biotechnol. 36, 777–778 (2018). Article CAS PubMed Google Scholar Scott, L. J. Givosiran: first approval. Drugs 80, 335–339 (2020). Article PubMed Google Scholar Scherphof, G. L., Dijkstra, J., Spanjer, H. H., Derksen, J. T. & Roerdink, F. H. Uptake and intracellular processing of targeted and nontargeted liposomes by rat Kupffer cells in vivo and in vitro. Ann. NY Acad. Sci. 446, 368–384 (1985). Article CAS PubMed Google Scholar Wu, G. Y. & Wu, C. H. Receptor-mediated in vitro gene transformation by a soluble DNA carrier system. J. Biol. Chem. 262, 4429–4432 (1987). Article CAS PubMed Google Scholar Baenziger, J. U. & Fiete, D. Galactose and N-acetylgalactosamine-specific endocytosis of glycopeptides by isolated rat hepatocytes. Cell 22, 611–620 (1980). Article CAS PubMed Google Scholar Nair, J. K. et al. Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J. Am. Chem. Soc. 136, 16958–16961 (2014). Article CAS PubMed Google Scholar Allen, T. M. & Cullis, P. R. Liposomal drug delivery systems: from concept to clinical applications. Adv. Drug Deliv. Rev. 65, 36–48 (2013). Article CAS PubMed Google Scholar Moghimi, S. M., Hunter, A. C. & Murray, J. C. Long-circulating and target-specific nanoparticles: theory to practice. Pharm. Rev. 53, 283–318 (2001). CAS PubMed Google Scholar Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603–2615 (2020). Article CAS PubMed Google Scholar Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2035389 (2020). Frenette, P. S., Pinho, S., Lucas, D. & Scheiermann, C. Mesenchymal stem cell: keystone of the hematopoietic stem cell niche and a stepping-stone for regenerative medicine. Annu. Rev. Immunol. 31, 285–316 (2013). Article PubMed Google Scholar Palucka, K. & Banchereau, J. Dendritic-cell-based therapeutic cancer vaccines. Immunity 39, 38–48 (2013). Article CAS PubMed PubMed Central Google Scholar June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S. & Milone, M. C. CAR T cell immunotherapy for human cancer. Science 359, 1361–1365 (2018). Article CAS PubMed Google Scholar Vargason, A. M. & Anselmo, A. C. Clinical translation of microbe-based therapies: current clinical landscape and preclinical outlook. Bioeng. Transl. Med. 3, 124–137 (2018). Article PubMed PubMed Central Google Scholar Prasad, V. Tisagenlecleucel—the first approved CAR-T-cell therapy: implications for payers and policy makers. Nat. Rev. Clin. Oncol. 15, 11–12 (2018). Article PubMed Google Scholar Jackson, H. J., Rafiq, S. & Brentjens, R. J. Driving CAR T-cells forward. Nat. Rev. Clin. Oncol. 13, 370–383 (2016). Article CAS PubMed PubMed Central Google Scholar Cheever, M. A. & Higano, C. S. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin. Cancer Res. 17, 3520–3526 (2011). Article PubMed Google Scholar Office of Tissues and Advanced Therapies. Approved Cellular and Gene Therapy Products https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products (US Food and Drug Adminstration, 2019). Riglar, D. T. & Silver, P. A. Engineering bacteria for diagnostic and therapeutic applications. Nat. Rev. Microbiol. 16, 214–225 (2018). Article CAS PubMed Google Scholar Volkman, R. & Offen, D. Concise review: mesenchymal stem cells in neurodegenerative diseases. Stem Cells 35, 1867–1880 (2017). Article PubMed Google Scholar Newick, K., O’Brien, S., Moon, E. & Albelda, S. M. CAR T cell therapy for solid tumors. Annu. Rev. Med. 68, 139–152 (2017). Article CAS PubMed Google Scholar Gargett, T. et al. GD2-specific CAR T cells undergo potent activation and deletion following antigen encounter but can be protected from activation-induced cell death by PD-1 blockade. Mol. Ther. 24, 1135–1149 (2016). Article CAS PubMed PubMed Central Google Scholar Fraietta, J. A. et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat. Med. 24, 563–571 (2018). Article CAS PubMed PubMed Central Google Scholar Hourd, P., Ginty, P., Chandra, A. & Williams, D. J. Manufacturing models permitting roll out/scale out of clinically led autologous cell therapies: regulatory and scientific challenges for comparability. Cytotherapy 16, 1033–1047 (2014). Article PubMed Google Scholar Levine, B. L., Miskin, J., Wonnacott, K. & Keir, C. Global manufacturing of CAR T cell therapy. Mol. Ther. Methods Clin. Dev. 4, 92–101 (2017). Article CAS PubMed Google Scholar Liu, Y., Guo, J. & Huang, L. Modulation of tumor microenvironment for immunotherapy: focus on nanomaterial-based strategies. Theranostics 10, 3099–3117 (2020). Article CAS PubMed PubMed Central Google Scholar Jarosławski, S. & Toumi, M. Sipuleucel-T (Provenge)—autopsy of an innovative paradigm change in cancer treatment: why a single-product biotech company failed to capitalize on its breakthrough invention. BioDrugs 29, 301–307 (2015). Article PubMed CAS Google Scholar Abou-El-Enein, M., Elsanhoury, A. & Reinke, P. Overcoming challenges facing advanced therapies in the EU market. Cell Stem Cell 19, 293–297 (2016). Article CAS PubMed Google Scholar Vegas, A. J. et al. Long-term glycemic control using polymer-encapsulated human stem cell-derived beta cells in immune-competent mice. Nat. Med. 22, 306–311 (2016). Article CAS PubMed PubMed Central Google Scholar Tang, L. et al. Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery. Nat. Biotechnol. 36, 707–716 (2018). Article CAS PubMed PubMed Central Google Scholar Stephan, M. T., Moon, J. J., Um, S. H., Bershteyn, A. & Irvine, D. J. Therapeutic cell engineering with surface-conjugated synthetic nanoparticles. Nat. Med. 16, 1035–1041 (2010). Article CAS PubMed PubMed Central Google Scholar Kauer, T. M., Figueiredo, J.-L., Hingtgen, S. & Shah, K. Encapsulated therapeutic stem cells implanted in the tumor resection cavity induce cell death in gliomas. Nat. Neurosci. 15, 197–204 (2012). Article CAS Google Scholar Gordh, T. Xylocain—a new local analgesic. Anaesthesia 4, 4–9 (1949). Article CAS PubMed Google Scholar Stanley, T. H. The history and development of the fentanyl series. J. Pain Symptom Manag. 7, S3–S7 (1992). Article CAS Google Scholar Tishler, M. in Molecular Modification in Drug Design Vol. 45 (ed. Schueler, F. W.) Ch. 1 (American Chemical Society, 1964). Pereira, D. A. & Williams, J. A. Origin and evolution of high throughput screening. Br. J. Pharmacol. 152, 53–61 (2007). Article CAS PubMed PubMed Central Google Scholar Lipinski, C. A., Lombardo, F., Dominy, B. W. & Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23, 3–25 (1997). Article CAS Google Scholar Hewitt, W. M. et al. Cell-permeable cyclic peptides from synthetic libraries inspired by natural products. J. Am. Chem. Soc. 137, 715–721 (2015). Article CAS PubMed Google Scholar Heinis, C. & Winter, G. Encoded libraries of chemically modified peptides. Curr. Opin. Chem. Biol. 26, 89–98 (2015). Article CAS PubMed Google Scholar Harris, J. M., Martin, N. E. & Modi, M. Pegylation: a novel process for modifying pharmacokinetics. Clin. Pharmacokinet. 40, 539–551 (2001). Article CAS PubMed Google Scholar Dunn, C. J., Plosker, G. L., Keating, G. M., McKeage, K. & Scott, L. J. Insulin glargine. Drugs 63, 1743–1778 (2003). Article CAS PubMed Google Scholar Jonassen, I. et al. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm. Res. 29, 2104–2114 (2012). Article CAS PubMed PubMed Central Google Scholar Birkeland, K. I. et al. Insulin degludec in type 1 diabetes. Diabetes Care 34, 661–665 (2011). Article PubMed PubMed Central Google Scholar Nelson, A. L., Dhimolea, E. & Reichert, J. M. Development trends for human monoclonal antibody therapeutics. Nat. Rev. Drug Discov. 9, 767–774 (2010). Article CAS PubMed Google Scholar Sievers, E. L. & Senter, P. D. Antibody–drug conjugates in cancer therapy. Annu. Rev. Med. 64, 15–29 (2013). Article CAS PubMed Google Scholar Benizri, S. et al. Bioconjugated oligonucleotides: recent developments and therapeutic applications. Bioconjug. Chem. 30, 366–383 (2019). Article CAS PubMed PubMed Central Google Scholar Anselmo, A. C. et al. Delivering nanoparticles to lungs while avoiding liver and spleen through adsorption on red blood cells. ACS Nano 7, 11129–11137 (2013). Article CAS PubMed PubMed Central Google Scholar Anselmo, A. C. & Mitragotri, S. Cell-mediated delivery of nanoparticles: taking advantage of circulatory cells to target nanoparticles. J. Control. Release 190, 531–541 (2014). Article CAS PubMed Google Scholar Roberts, M. J., Bentley, M. D. & Harris, J. M. Chemistry for peptide and protein PEGylation. Adv. Drug Deliv. Rev. 54, 459–476 (2002). Article CAS PubMed Google Scholar DeLoach, J. R. & Sprandel, U. (eds) in Bibliotheca Haematologica Vol. 51 (Karger, 1985). Stephan, M. T. & Irvine, D. J. Enhancing cell therapies from the outside in: cell surface engineering using synthetic nanomaterials. Nano Today 6, 309–325 (2011). Article CAS PubMed PubMed Central Google Scholar Villa, C. H., Anselmo, A. C., Mitragotri, S. & Muzykantov, V. Red blood cells: supercarriers for drugs, biologicals, and nanoparticles and inspiration for advanced delivery systems. Adv. Drug Deliv. Rev. 106, 88–103 (2016). Article CAS PubMed PubMed Central Google Scholar Song, W., Anselmo, A. C. & Huang, L. Nanotechnology intervention of the microbiome for cancer therapy. Nat. Nanotechnol. 14, 1093–1103 (2019). Article CAS PubMed Google Scholar Ashmore-Harris, C. & Fruhwirth, G. O. The clinical potential of gene editing as a tool to engineer cell-based therapeutics. Clin. Transl. Med. 9, 15 (2020). Article PubMed PubMed Central Google Scholar Xu, X., Ho, W., Zhang, X., Bertrand, N. & Farokhzad, O. Cancer nanomedicine: from targeted delivery to combination therapy. Trends Mol. Med. 21, 223–232 (2015). Article CAS PubMed PubMed Central Google Scholar Bago, J. R. et al. Therapeutically engineered induced neural stem cells are tumour-homing and inhibit progression of glioblastoma. Nat. Commun. 7, 10593 (2016). Article CAS PubMed PubMed Central Google Scholar Pagliuca, F. W. et al. Generation of functional human pancreatic beta cells in vitro. Cell 159, 428–439 (2014). Article CAS PubMed PubMed Central Google Scholar Smith, T. T. et al. In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers. Nat. Nanotechnol. 12, 813–820 (2017). Article CAS PubMed PubMed Central Google Scholar Cheng, Q. et al. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR–Cas gene editing. Nat. Nanotechnol. 15, 313–320 (2020). Article CAS PubMed PubMed Central Google Scholar Goldberg, M. S. Improving cancer immunotherapy through nanotechnology. Nat. Rev. Cancer 19, 587–602 (2019). Article CAS PubMed Google Scholar Song, W. et al. Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap. Nat. Commun. 9, 2237 (2018). Article PubMed PubMed Central CAS Google Scholar Shields, C. W. IV. et al. Cellular backpacks for macrophage immunotherapy. Sci. Adv. 6, eaaz6579 (2020). Article CAS PubMed PubMed Central Google Scholar Cao, P. et al. Abstract 3577: application of deep IL-15 backpacks to human T cells demonstrates tunable loading with enhanced cell proliferation and antitumor activity. Cancer Res. 78(Suppl.), 3577 (2018). Google Scholar Flanagan, T. Potential for pharmaceutical excipients to impact absorption: a mechanistic review for BCS class 1 and 3 drugs. Eur. J. Pharm. Biopharm. 141, 130–138 (2019). Article CAS PubMed Google Scholar Breda, S. A., Jimenez-Kairuz, A. F., Manzo, R. H. & Olivera, M. E. Solubility behavior and biopharmaceutical classification of novel high-solubility ciprofloxacin and norfloxacin pharmaceutical derivatives. Int. J. Pharm. 371, 106–113 (2009). Article CAS PubMed Google Scholar Taniguchi, C., Kawabata, Y., Wada, K., Yamada, S. & Onoue, S. Microenvironmental pH-modification to improve dissolution behavior and oral absorption for drugs with pH-dependent solubility. Expert Opin. Drug Deliv. 11, 505–516 (2014). Article CAS PubMed Google Scholar Lostalé-Seijo, I. & Montenegro, J. Synthetic materials at the forefront of gene delivery. Nat. Rev. Chem. 2, 258–277 (2018). Article Google Scholar Evans, B. C. et al. An anionic, endosome-escaping polymer to potentiate intracellular delivery of cationic peptides, biomacromolecules, and nanoparticles. Nat. Commun. 10, 5012 (2019). Article PubMed PubMed Central CAS Google Scholar Hafez, I. M., Maurer, N. & Cullis, P. R. On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids. Gene Ther. 8, 1188–1196 (2001). Article CAS PubMed Google Scholar Wan, C., Allen, T. & Cullis, P. Lipid nanoparticle delivery systems for siRNA-based therapeutics. Drug Deliv. Transl. Res. 4, 74–83 (2014). Article CAS PubMed Google Scholar Welling, S. H. et al. The role of citric acid in oral peptide and protein formulations: relationship between calcium chelation and proteolysis inhibition. Eur. J. Pharm. Biopharm. 86, 544–551 (2014). Article CAS PubMed Google Scholar Chen, S. et al. Dexamethasone prodrugs as potent suppressors of the immunostimulatory effects of lipid nanoparticle formulations of nucleic acids. J. Control. Release 286, 46–54 (2018). Article CAS PubMed Google Scholar Scarfo, I. & Maus, M. V. Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment. J. Immunother. Cancer 5, 28 (2017). Article PubMed PubMed Central Google Scholar Shum, T. et al. Constitutive signaling from an engineered IL7 receptor promotes durable tumor elimination by tumor-redirected T cells. Cancer Discov. 7, 1238–1247 (2017). Article CAS PubMed PubMed Central Google Scholar Berger, C. et al. Safety and immunologic effects of IL-15 administration in nonhuman primates. Blood 114, 2417–2426 (2009). Article CAS PubMed PubMed Central Google Scholar Lotze, M. T. et al. In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J. Immunol. 135, 2865–2875 (1985). CAS PubMed Google Scholar Yeku, O. O. & Brentjens, R. J. Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy. Biochem. Soc. Trans. 44, 412–418 (2016). Article CAS PubMed PubMed Central Google Scholar Di Stasi, A. et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 365, 1673–1683 (2011). Article PubMed PubMed Central Google Scholar Ma, X. et al. Interleukin-23 engineering improves CAR T cell function in solid tumors. Nat. Biotechnol. 38, 448–459 (2020). Article CAS PubMed PubMed Central Google Scholar Hamilton, M. J., Weingarden, A. R., Unno, T., Khoruts, A. & Sadowsky, M. J. High-throughput DNA sequence analysis reveals stable engraftment of gut microbiota following transplantation of previously frozen fecal bacteria. Gut Microbes 4, 125–135 (2013). Article PubMed PubMed Central Google Scholar Lee, S. & Margolin, K. Cytokines in cancer immunotherapy. Cancers 3, 3856–3893 (2011). Article CAS PubMed PubMed Central Google Scholar Grayson, M. L. et al. Kucers’ The Use of Antibiotics Sixth Edition: A Clinical Review of Antibacterial, Antifungal and Antiviral Drugs (CRC Press, 2010). Dou, H. et al. Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS. J. Immunol. 183, 661–669 (2009). Article CAS PubMed Google Scholar Brynskikh, A. M. et al. Macrophage delivery of therapeutic nanozymes in a murine model of Parkinson’s disease. Nanomedicine 5, 379–396 (2010). Article CAS PubMed Google Scholar Mimee, M., Tucker, A. C., Voigt, C. A. & Lu, T. K. Programming a human commensal bacterium, Bacteroides thetaiotaomicron, to sense and respond to stimuli in the murine gut microbiota. Cell Syst. 1, 62–71 (2015). Article CAS PubMed PubMed Central Google Scholar Charbonneau, M. R., Isabella, V. M., Li, N. & Kurtz, C. B. Developing a new class of engineered live bacterial therapeutics to treat human diseases. Nat. Commun. 11, 1738–1738 (2020). Article CAS PubMed PubMed Central Google Scholar Robinson, J. R. & Lee, V. H. (eds) Controlled Drug Delivery: Fundamentals and Applications (Dekker, 1987). Owens, D. E. III & Peppas, N. A. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm. 307, 93–102 (2006). Article CAS PubMed Google Scholar Tiwari, G. et al. Drug delivery systems: an updated review. Int. J. Pharm. Investig. 2, 2–11 (2012). Article PubMed PubMed Central CAS Google Scholar Kamaly, N., Yameen, B., Wu, J. & Farokhzad, O. C. Degradable controlled-release polymers and polymeric nanoparticles: mechanisms of controlling drug release. Chem. Rev. 116, 2602–2663 (2016). Article CAS PubMed PubMed Central Google Scholar Rosen, H. & Abribat, T. The rise and rise of drug delivery. Nat. Rev. Drug Discov. 4, 381–385 (2005). Article CAS PubMed Google Scholar Cole, E. T. et al. Enteric coated HPMC capsules designed to achieve intestinal targeting. Int. J. Pharm. 231, 83–95 (2002). Article CAS PubMed Google Scholar Carino, G. P. & Mathiowitz, E. Oral insulin delivery. Adv. Drug Deliv. Rev. 35, 249–257 (1999). Article CAS PubMed Google Scholar Lane, M. E. Skin penetration enhancers. Int. J. Pharm. 447, 12–21 (2013). Article CAS PubMed Google Scholar Schwendeman, S. P., Shah, R. B., Bailey, B. A. & Schwendeman, A. S. Injectable controlled release depots for large molecules. J. Control. Release 190, 240–253 (2014). Article CAS PubMed PubMed Central Google Scholar Awwad, S. & Angkawinitwong, U. Overview of antibody drug delivery. Pharmaceutics 10, 83 (2018). Article CAS PubMed Central Google Scholar McKay, W. F., Peckham, S. M. & Badura, J. M. A comprehensive clinical review of recombinant human bone morphogenetic protein-2 (INFUSE Bone Graft). Int. Orthop. 31, 729–734 (2007). Article PubMed PubMed Central Google Scholar Geho, W. B., Geho, H. C., Lau, J. R. & Gana, T. J. Hepatic-directed vesicle insulin: a review of formulation development and preclinical evaluation. J. Diabetes Sci. Technol. 3, 1451–1459 (2009). Article PubMed PubMed Central Google Scholar Baselga, J. Clinical trials of Herceptin (trastuzumab). Eur. J. Cancer 37, 18–24 (2001). Article PubMed Google Scholar Coats, S. et al. Antibody–drug conjugates: future directions in clinical and translational strategies to improve the therapeutic index. Clin. Cancer Res. 25, 5441–5448 (2019). Article CAS PubMed Google Scholar Verma, S. et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N. Engl. J. Med. 367, 1783–1791 (2012). Article CAS PubMed PubMed Central Google Scholar Gao, X. & Huang, L. Cationic liposome-mediated gene transfer. Gene Ther. 2, 710–722 (1995). CAS PubMed Google Scholar Zelphati, O. & Szoka, F. C. Mechanism of oligonucleotide release from cationic liposomes. Proc. Natl Acad. Sci. USA 93, 11493–11498 (1996). Article CAS PubMed PubMed Central Google Scholar Friend, D. S., Papahadjopoulos, D. & Debs, R. J. Endocytosis and intracellular processing accompanying transfection mediated by cationic liposomes. Biochim. Biophys. Acta 1278, 41–50 (1996). Article PubMed Google Scholar Nabel, G. J. et al. Direct gene transfer with DNA–liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc. Natl Acad. Sci. USA 90, 11307–11311 (1993). Article CAS PubMed PubMed Central Google Scholar Filion, M. C. & Phillips, N. C. Major limitations in the use of cationic liposomes for DNA delivery. Int. J. Pharm. 162, 159–170 (1998). Article CAS Google Scholar Lv, H., Zhang, S., Wang, B., Cui, S. & Yan, J. Toxicity of cationic lipids and cationic polymers in gene delivery. J. Control. Release 114, 100–109 (2006). Article CAS PubMed Google Scholar Semple, S. C. et al. Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures. Biochim. Biophys. Acta 1510, 152–166 (2001). Article CAS PubMed Google Scholar Semple, S. C. et al. Rational design of cationic lipids for siRNA delivery. Nat. Biotechnol. 28, 172–176 (2010). Article CAS PubMed Google Scholar Akinc, A. et al. The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs. Nat. Nanotechnol. 14, 1084–1087 (2019). Article CAS PubMed Google Scholar Vegas, A. J. et al. Combinatorial hydrogel library enables identification of materials that mitigate the foreign body response in primates. Nat. Biotechnol. 34, 345–352 (2016). Article CAS PubMed PubMed Central Google Scholar Bochenek, M. A. et al. Alginate encapsulation as long-term immune protection of allogeneic pancreatic islet cells transplanted into the omental bursa of macaques. Nat. Biomed. Eng. 2, 810–821 (2018). Article CAS PubMed PubMed Central Google Scholar Grøndahl, L., Lawrie, G., Anitha, A. & Shejwalkar, A. in Biointegration of Medical Implant Materials 2nd edn (ed. Sharma, C. P.) 375–403 (Woodhead Publishing, 2020). Okita, K., Ichisaka, T. & Yamanaka, S. Generation of germline-competent induced pluripotent stem cells. Nature 448, 313–317 (2007). Article CAS PubMed Google Scholar Carmona, G. et al. Correcting rare blood disorders using coagulation factors produced in vivo by Shielded Living Therapeutics products. Blood 134, 2065 (2019). Article Google Scholar Stephan, S. B. et al. Biopolymer implants enhance the efficacy of adoptive T-cell therapy. Nat. Biotechnol. 33, 97–101 (2015). Article CAS PubMed Google Scholar Mao, A. S. et al. Programmable microencapsulation for enhanced mesenchymal stem cell persistence and immunomodulation. Proc. Natl Acad. Sci. USA 116, 15392–15397 (2019). Article CAS PubMed PubMed Central Google Scholar Lipsitz, Y. Y., Timmins, N. E. & Zandstra, P. W. Quality cell therapy manufacturing by design. Nat. Biotechnol. 34, 393–400 (2016). Article CAS PubMed Google Scholar Malik, N. N. & Durdy, M. B. in Translational Regenerative Medicine (eds Atala, A. & Allickson, J. G.) 87–106 (Elsevier, 2015). Ding, X. et al. High-throughput nuclear delivery and rapid expression of DNA via mechanical and electrical cell-membrane disruption. Nat. Biomed. Eng. 1, 0039 (2017). Article CAS PubMed PubMed Central Google Scholar Riley, R. S., June, C. H., Langer, R. & Mitchell, M. J. Delivery technologies for cancer immunotherapy. Nat. Rev. Drug Discov. 18, 175–196 (2019). Article CAS PubMed PubMed Central Google Scholar Zhang, W.-W. et al. The first approved gene therapy product for cancer Ad-p53 (Gendicine): 12 years in the clinic. Hum. Gene Ther. 29, 160–179 (2018). Article CAS PubMed Google Scholar Devaud, C., John, L. B., Westwood, J. A., Darcy, P. K. & Kershaw, M. H. Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy. OncoImmunology 2, e25961 (2013). Article PubMed PubMed Central Google Scholar Dane, K. Y. et al. Nano-sized drug-loaded micelles deliver payload to lymph node immune cells and prolong allograft survival. J. Control. Release 156, 154–160 (2011). Article CAS PubMed Google Scholar Eggermont, L. J., Paulis, L. E., Tel, J. & Figdor, C. G. Towards efficient cancer immunotherapy: advances in developing artificial antigen-presenting cells. Trends Biotechnol. 32, 456–465 (2014). Article CAS PubMed PubMed Central Google Scholar Deshayes, S., Morris, M. C., Divita, G. & Heitz, F. Cell-penetrating peptides: tools for intracellular delivery of therapeutics. Cell. Mol. Life Sci. 62, 1839–1849 (2005). Article CAS PubMed Google Scholar Adler, L. A. et al. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study. J. Clin. Psychopharmacol. 29, 239–247 (2009). Article CAS PubMed Google Scholar Jana, S., Mandlekar, S. & Marathe, P. Prodrug design to improve pharmacokinetic and drug delivery properties: challenges to the discovery scientists. Curr. Med. Chem. 17, 3874–3908 (2010). Article CAS PubMed Google Scholar Swinney, D. C. & Anthony, J. How were new medicines discovered? Nat. Rev. Drug Discov. 10, 507–519 (2011). Article CAS PubMed Google Scholar Chey, W. D. et al. Naloxegol for opioid-induced constipation in patients with noncancer pain. N. Engl. J. Med. 370, 2387–2396 (2014). Article PubMed CAS Google Scholar Agersø, H. et al. Pharmacokinetics and renal excretion of desmopressin after intravenous administration to healthy subjects and renally impaired patients. Br. J. Clin. Pharm. 58, 352–358 (2004). Article CAS Google Scholar Al-Tabakha, M. M. Future prospect of insulin inhalation for diabetic patients: the case of Afrezza versus Exubera. J. Control. Release 215, 25–38 (2015). Article CAS PubMed Google Scholar Booth, C. & Gaspar, H. B. Pegademase bovine (PEG-ADA) for the treatment of infants and children with severe combined immunodeficiency (SCID). Biologics 3, 349–358 (2009). CAS PubMed PubMed Central Google Scholar Larsen, C. P. et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am. J. Transplant. 5, 443–453 (2005). Article CAS PubMed Google Scholar Pasut, G. Pegylation of biological molecules and potential benefits: pharmacological properties of certolizumab pegol. BioDrugs 28, 15–23 (2014). Article Google Scholar Mensink, M. A., Frijlink, H. W., van der Voort Maarschalk, K. & Hinrichs, W. L. How sugars protect proteins in the solid state and during drying (review): mechanisms of stabilization in relation to stress conditions. Eur. J. Pharm. Biopharm. 114, 288–295 (2017). Article CAS PubMed Google Scholar Sanford, M. Subcutaneous trastuzumab: a review of its use in HER2-positive breast cancer. Target. Oncol. 9, 85–94 (2014). Article PubMed Google Scholar Cohenuram, M. & Saif, M. W. Panitumumab the first fully human monoclonal antibody: from the bench to the clinic. Anti-cancer Drugs 18, 7–15 (2007). Article CAS PubMed Google Scholar Hu, Q. et al. in Development of Biopharmaceutical Drug-Device Products (eds Jameel, F. et al.) 343–372 (Springer International Publishing, 2020). Eckstein, F. Phosphorothioates, essential components of therapeutic oligonucleotides. Nucleic Acid Ther. 24, 374–387 (2014). Article CAS PubMed Google Scholar Springer, A. D. & Dowdy, S. F. GalNAc–siRNA conjugates: leading the way for delivery of RNAi therapeutics. Nucleic Acid Ther. 28, 109–118 (2018). Article CAS PubMed PubMed Central Google Scholar Corey, D. R. Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy. Nat. Neurosci. 20, 497–499 (2017). Article CAS PubMed Google Scholar Xu, L. et al. CRISPR-edited stem cells in a patient with HIV and acute lymphocytic leukemia. N. Engl. J. Med. 381, 1240–1247 (2019). Article CAS PubMed Google Scholar Brudno, J. N. & Kochenderfer, J. N. Chimeric antigen receptor T-cell therapies for lymphoma. Nat. Rev. Clin. Oncol. 15, 31–46 (2018). Article CAS PubMed Google Scholar Bartlett, W. et al. Autologous chondrocyte implantation versus matrix-induced autologous chondrocyte implantation for osteochondral defects of the knee: a prospective, randomised study. J. Bone Joint Surg. Br. 87, 640–645 (2005). Article CAS PubMed Google Scholar Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439–448 (2018). Article CAS PubMed PubMed Central Google Scholar Fordtran, J. S. & Hofmann, A. F. Seventy years of polyethylene glycols in gastroenterology: the journey of PEG 4000 and 3350 from nonabsorbable marker to colonoscopy preparation to osmotic laxative. Gastroenterology 152, 675–680 (2017). Article PubMed Google Scholar Abuchowski, A., van Es, T., Palczuk, N. C. & Davis, F. F. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J. Biol. Chem. 252, 3578–3581 (1977). Article CAS PubMed Google Scholar Liu, K.-J. & Parsons, J. L. Solvent effects on the preferred conformation of poly(ethylene glycols). Macromolecules 2, 529–533 (1969). Article CAS Google Scholar Maxfield, J. & Shepherd, I. Conformation of poly (ethylene oxide) in the solid state, melt and solution measured by Raman scattering. Polymer 16, 505–509 (1975). Article CAS Google Scholar Turecek, P. L., Bossard, M. J., Schoetens, F. & Ivens, I. A. PEGylation of biopharmaceuticals: a review of chemistry and nonclinical safety information of approved drugs. J. Pharm. Sci. 105, 460–475 (2016). Article CAS PubMed Google Scholar Klibanov, A. L., Maruyama, K., Torchilin, V. P. & Huang, L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 268, 235–237 (1990). Article CAS PubMed Google Scholar Rohlke, F. & Stollman, N. Fecal microbiota transplantation in relapsing Clostridium difficile infection. Therap. Adv. Gastroenterol. 5, 403–420 (2012). Article PubMed PubMed Central Google Scholar Li, W., Zhan, P., De Clercq, E., Lou, H. & Liu, X. Current drug research on PEGylation with small molecular agents. Prog. Polym. Sci. 38, 421–444 (2013). Article CAS Google Scholar Yang, Q. & Lai, S. K. Anti‐PEG immunity: emergence, characteristics, and unaddressed questions. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 7, 655–677 (2015). Article PubMed PubMed Central CAS Google Scholar Mora, J. R., White, J. T. & DeWall, S. L. Immunogenicity risk assessment for PEGylated therapeutics. AAPS J. 22, 35 (2020). Article CAS PubMed Google Scholar Wang, X., Ishida, T. & Kiwada, H. Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes. J. Control. Release 119, 236–244 (2007). Article CAS PubMed Google Scholar Povsic, T. J. et al. Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer. J. Allergy Clin. Immunol. 138, 1712–1715 (2016). Article CAS PubMed Google Scholar Bauer, M. et al. Poly (2‐ethyl‐2‐oxazoline) as alternative for the stealth polymer poly (ethylene glycol): comparison of in vitro cytotoxicity and hemocompatibility. Macromol. Biosci. 12, 986–998 (2012). Article CAS PubMed Google Scholar Knop, K., Hoogenboom, R., Fischer, D. & Schubert, U. S. Poly (ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew. Chem. Int. Ed. 49, 6288–6308 (2010). Article CAS Google Scholar Zhang, P. et al. Polypeptides with high zwitterion density for safe and effective therapeutics. Angew. Chem. Int. Ed. 57, 7743–7747 (2018). Article CAS Google Scholar Rodriguez, P. L. et al. Minimal “self” peptides that inhibit phagocytic clearance and enhance delivery of nanoparticles. Science 339, 971–975 (2013). Article CAS PubMed PubMed Central Google Scholar Sosale, N. G. et al. ‘Marker of Self’ CD47 on lentiviral vectors decreases macrophage-mediated clearance and increases delivery to SIRPA-expressing lung carcinoma tumors. Mol. Ther. Methods Clin. Dev. 3, 16080 (2016). Article PubMed PubMed Central CAS Google Scholar Shereen, M. A., Khan, S., Kazmi, A., Bashir, N. & Siddique, R. COVID-19 infection: origin, transmission, and characteristics of human coronaviruses. J. Adv. Res. 24, 91–98 (2020). Article CAS PubMed PubMed Central Google Scholar Lipsitch, M., Swerdlow, D. L. & Finelli, L. Defining the epidemiology of Covid-19—studies needed. N. Engl. J. Med. 382, 1194–1196 (2020). Article CAS PubMed Google Scholar Shin, M. D. et al. COVID-19 vaccine development and a potential nanomaterial path forward. Nat. Nanotechnol. 15, 646–655 (2020). Article CAS PubMed Google Scholar Chen, W. H., Strych, U., Hotez, P. J. & Bottazzi, M. E. The SARS-CoV-2 vaccine pipeline: an overview. Curr. Trop. Med. Rep. 7, 61–64 (2020). Article Google Scholar Le, T. T. et al. The COVID-19 vaccine development landscape. Nat. Rev. Drug Discov. 19, 305–306 (2020). Article CAS Google Scholar Florindo, H. F. et al. Immune-mediated approaches against COVID-19. Nat. Nanotechnol. 15, 630–645 (2020). Article CAS PubMed Google Scholar McHugh, K. J., Guarecuco, R., Langer, R. & Jaklenec, A. Single-injection vaccines: progress, challenges, and opportunities. J. Control. Release 219, 596–609 (2015). Article CAS PubMed Google Scholar Arya, J. & Prausnitz, M. R. Microneedle patches for vaccination in developing countries. J. Control. Release 240, 135–141 (2016). Article CAS PubMed Google Scholar Zaman, M., Chandrudu, S. & Toth, I. Strategies for intranasal delivery of vaccines. Drug Deliv. Transl. Res. 3, 100–109 (2013). Article CAS PubMed Google Scholar Feldman, R. A. et al. mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials. Vaccine 37, 3326–3334 (2019). Article CAS PubMed Google Scholar Kose, N. et al. A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection. Sci. Immunol. 4, eaaw6647 (2019). Article CAS PubMed PubMed Central Google Scholar Richner, J. M. et al. Modified mRNA vaccines protect against Zika virus infection. Cell 168, 1114–1125.e10 (2017). Article CAS PubMed PubMed Central Google Scholar Amante, D. H. et al. Skin transfection patterns and expression kinetics of electroporation-enhanced plasmid delivery using the CELLECTRA-3P, a portable next-generation dermal electroporation device. Hum. Gene Ther. Methods 26, 134–146 (2015). Article CAS PubMed PubMed Central Google Scholar McHugh, K. J. Employing drug delivery strategies to create safe and effective pharmaceuticals for COVID-19. Bioeng. Transl. Med. 5, e10163 (2020). Article CAS PubMed PubMed Central Google Scholar Singh, S. et al. Allogeneic cardiosphere-derived cells (CAP-1002) in critically ill COVID-19 patients: compassionate-use case series. Basic Res. Cardiol. 115, 36 (2020). Article CAS PubMed PubMed Central Google Scholar Har-Noy, M. & Or, R. Allo-priming as a universal anti-viral vaccine: protecting elderly from current COVID-19 and any future unknown viral outbreak. J. Transl. Med. 18, 196 (2020). Article CAS PubMed PubMed Central Google Scholar Which of the following describes the chemical changes made to a drug by the body?Metabolism describes the chemical reactions that change drugs into compounds which are easier to eliminate. The products of these chemical reactions are called metabolites.
Is the chemical alteration that a drug undergoes in the body usually in the liver?Most drugs undergo chemical alteration by various bodily systems to create compounds that are more easily excreted from the body. These chemical alterations occur primarily in the liver and are known as biotransformations.
Which step describes the biochemical alteration of a drug into an active or inactive metabolite?Biotransformation occurs mainly in the liver and produces a metabolite that is either inactive or active. Also known as metabolism.
Which of the following is the process by which drug molecules are transformed into simpler products that can be utilized in the body?The process by which drug molecules are transformed into simpler products is called: metabolism Flashcards | Quizlet.
|
Which of the following is the chemical alteration of drug molecules into metabolites by body cells?
zusammenhängende Posts
Urheberrechte © © 2024 de.ketajaman Inc.
